Skip to main content

Table 4 Overall summary of AEs

From: Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the Icatibant Outcome Survey

 

Elderly (≥ 65 years)

Younger (< 65 years)

Patients (n = 100)

Events

Patients (n = 772)

Events

Total AEs, n (%)

28 (28.0)

86 (100.0)

164 (21.2)

374 (100.0)

Occurrence of ≥ 1 icatibant-related AE, n (%)

2 (2.0)

19 (22.1)

21 (2.7)

68 (18.2)

AEs by relationship to icatibant use, n (%)

    

 Not recorded

0 (0.0)

0 (0.0)

11 (1.4)

28 (7.5)

 Not related

26 (26.0)

67 (77.9)

132 (17.1)

278 (74.3)

 Possibly related

0 (0.0)

0 (0.0)

5 (0.6)

34 (9.1)

 Probably related

2 (2.0)

19 (22.1)

16 (2.1)

34 (9.1)

Icatibant-related AEs by seriousness, n (%)

    

 Serious

0 (0.0)

0 (0.0)

2 (0.3)

3 (4.4)

 Not serious

2 (2.0)

19 (100.0)

19 (2.5)

65 (95.6)

  1. AE adverse event